An easy-to-consume, heat-stable, fixed-dose combination of four antiretrovirals (ARVs) developed for HIV-infected infants and young children weighing 3 to 25 kg is currently under review by the US Food and Drug Administration (FDA).
If approved by the FDA, this all-in-one regimen, consisting of the four antiretroviral medicines lopinavir, ritonavir, abac…